Enrollment for 2018 in Affordable Care Act plans is only slightly below figures from 2017; a rare breed of antibiotic-resistant bacteria is spreading in hospitals; a new company will develop off-the-shelf CAR T-cell therapies that do not need to be personalized to the patient.
The final figures for enrollment in Affordable Care Act insurance plans showed that 11.8 million signed up in 2018. According to The Washington Post, the numbers represent a slight dip of just 400,000 from 2017. Enrollment in states that operated their own marketplaces was flat, while enrollment dropped in the 39 states on the federal marketplace. The proportion of consumers qualifying for subsidies remained level at 83%, while first-time consumers dropped from 31% to 27% of all enrollees.
In 2017, there were more than 220 cases of a rare breed of bacteria that is mostly untreatable, and which has taken CDC by surprise. Up to half of infections caused by these superbugs are fatal, reported Kaiser Health News. In addition, 1 in 10 cases of people infected with the germs spread the disease to healthy people who act as silent carriers. The good news is that hospitals can limit the spread of outbreaks from these bacteria with aggressive measures, such as wearing gowns and gloves while caring for infected patients. Containing these infections can reduce them by 76%.
Chimeric antigen receptor (CAR) T-cell therapies need to be personalized to each patient, but a new company is looking to develop off-the-shelf therapies that do not need to be personalized. Allogene Therapeutics was launched Tuesday by 2 former executives of Kite Pharma and has bought Pfizer’s portfolio of cell therapies, according to STAT. The new approach would harvest and modify cells taken from a healthy donor to then use to treat any eligible patient with cancer. Currently, CAR T therapies are made by collecting cells from a patient with cancer, modifying them, and reinfusing the cells back into the patient. While current CAR T-cell therapies have been highly successful, it is time consuming to create them.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More